MLTX
MoonLake·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Stock Price Surged Significantly
Ample Liquidity
Significant Net Income Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MLTX
Moonlake Immunotherapeutics.
A clinical-stage biotech company that develops medicines for immunologic diseases, including inflammatory skin and joint diseases
Biological Technology
08/13/2020
10/20/2020
NASDAQ Stock Exchange
100
12-31
Common stock
Dorfstrasse 29, 6300 Zug, Switzerland
--
MoonLake Immunotherapeutics. A Cayman Islands company registered on August 13, 2020, MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing transformative therapies to address significant unmet needs in inflammatory skin and joint diseases.
Company Financials
EPS
MLTX has released its 2025 Q3 earnings. EPS was reported at -1.1, versus the expected -0.92, missing expectations. The chart below visualizes how MLTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
